Aridis Pharmaceuticals, Inc.
5941 Optical Court
San Jose
California
95138
United States
Tel: 408-385-1742
Fax: 408-960-3822
Website: http://www.aridispharma.com/
78 articles with Aridis Pharmaceuticals, Inc.
-
Aridis Pharmaceuticals Announces First Quarter 2021 Results
5/11/2021
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, reported financial and corporate results for the first quarter ended March 31, 2021.
-
Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update
3/30/2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the fourth quarter ended December 31, 2020.
-
Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
3/26/2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced an interview with Vu Truong, Ph.D., Chief Executive Officer will air on The RedChip Money Report®
-
Aridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode
3/8/2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. Kermode works on vaccines and mAbs for zoonotic viruses, which are animal viruses that have the ability to infect humans.
-
Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants
2/23/2021
National Institute of Allergy and Infectious Disease (NIAID) and the Coronavirus Immunotherapy Consortium (CoVIC) are providing preclinical services support to accelerate development
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
-
Aridis' COVID-19 therapy is particularly exciting. AR-711 is an inhaled, self-administered, at-home treatment for mild-to-moderate SARS-CoV-2 infections.
-
Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020
11/24/2020
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, is pleased to announce a 75 minute "Fireside Chat Forum," with its five covering analysts will be held on December 4th, 2020 at 11:00AM EST.
-
Aridis Pharmaceuticals Announces Third Quarter 2020 Results
11/20/2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the third quarter ended September 30, 2020.
-
Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel
10/27/2020
Aridis Pharmaceuticals, Inc. announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
-
Aridis CEO Confident Inhaled Antibody Formulation Will Play a Key Role in Controlling COVID-19
10/26/2020
Only a fraction of intravenous antibody treatments will make their way to the lungs of COVID-19 patients, which is where the infection is primarily located. Aridis Chief Executive Officer Vu Truong believes his company has a better solution – an inhaled antibody. -
Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients
10/19/2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the development of a highly neutralizing monoclonal antibody AR-711, discovered from convalescent COVID-19 patients, that success
-
Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering
10/14/2020
Aridis Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors with extensive backgrounds in life sciences and biotechnology investing to purchase in a registered direct offering 1,134,470 shares of common stock for $7.4925 per share.
-
Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501
9/8/2020
Aridis Pharmaceuticals, Inc. announced it has reached an agreement with the US Food and Drug Administration to simplify the Company's AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis.
-
Aridis Pharmaceuticals to Present at Upcoming Investor Conferences
9/4/2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong , Ph.D., Chief Executive Officer, will present at the following investor conferences in September:
-
Aridis Pharmaceuticals Announces Second Quarter 2020 Results
8/11/2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the second quarter ended June 30, 2020. Second Quarter Highlights and Recent Developments
-
Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
6/26/2020
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced that Vu Truong, Ph.D., Chief Executive Officer, will participate in Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19" being held on Tuesday, June 30, 2020.
-
Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial
6/22/2020
Phase 1 portion of the Phase 1/2a trial, 48 healthy volunteers were treated with either single or multiple weekly dose regimens
-
Aridis Pharmaceuticals to Discuss APEX™ in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th
6/18/2020
Showcasing the Company's new technology platform geared to rapidly discover new treatments for emerging pulmonary pathogens